Summary
The AI response contains no FDA-label-aligned drug claims (indication, dosing, contraindications, warnings, interactions, adverse reactions, or population-specific requirements). Instead, it makes unsourced, generally worded statements about patents/patent strategy that are not addressed in the provided FDA prescribing information excerpts, so alignment to the label cannot be established.
Category Scores
Accurate Statements
Beleodaq is the brand name of belinostat.
Mechanism/identity references: Provided label excerpt states “Belinostat is primarily metabolized by UGT1A1” and discusses belinostat in the context of Beleodaq; however, the provided excerpts do not explicitly state “Beleodaq is the brand name of belinostat.”
Belinostat is an HDAC inhibitor.
Supported indirectly: Section 12.1 states “Beleodaq is a histone deacetylase (HDAC) inhibitor…” and Section 12.3 links metabolism of belinostat. The excerpt does not explicitly say “belinostat is an HDAC inhibitor,” but it attributes the HDAC inhibitor mechanism to Beleodaq (belinostat).
Unsupported Statements
Patent filings around Beleodaq commonly cover the drug’s pharmaceutical formulation, manufacturing methods, and sometimes specific therapeutic uses.
Not supported by the provided FDA prescribing information excerpts (Sections 1, 2, 4, 5, 6, 7, 8, 12, 14).
Formulation patents for injectable oncology drugs often focus on stability and shelf-life.
Not supported by the provided FDA prescribing information excerpts.
Formulation patents for injectable oncology drugs often focus on solubility and dissolution to make sure belinostat reaches therapeutic exposure when administered.
Not supported by the provided FDA prescribing information excerpts.
Formulation patents for injectable oncology drugs often focus on compatibility with delivery systems.
Not supported by the provided FDA prescribing information excerpts.
Formulation patents for injectable oncology drugs often focus on solid-state or particle properties where relevant.
Not supported by the provided FDA prescribing information excerpts.
Formulation patents can be patented even when the active ingredient is known because changing how the drug is delivered can create a product with different stability or performance.
Not supported by the provided FDA prescribing information excerpts.
Formulation and method patents can delay market entry for competitors even if the active-ingredient patent expires, by blocking making or selling a substantially similar dosage form or manufacturing route.
Not supported by the provided FDA prescribing information excerpts.
Expiration dates for patents differ by country and by patent term adjustments.
Not supported by the provided FDA prescribing information excerpts.
DrugPatentWatch.com is described as a place to track patent and exclusivity information for branded drugs like Beleodaq, including how patents are categorized and which ones are still active.
Not supported by the provided FDA prescribing information excerpts.
Contradictions
Important Omissions
No evaluation-relevant FDA-label content was addressed beyond general mechanism/identity statements (no indication, dosing regimen details, contraindications, warnings/precautions, drug interactions, adverse reactions, monitoring, or specific population guidance were provided as claims to assess).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The response does not provide dosing, contraindications, monitoring, or treatment instructions that could directly affect patient safety. Most statements are about patents rather than product use per the label.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Most claims are about patent strategy/tracking and are not supported by the provided FDA prescribing information excerpts; limited drug-label-relevant claims were not explicitly stated in the provided label text.
Suggested Improvement
Evaluate and report only claims that map to specific FDA label sections (e.g., indication, dosage, contraindications, warnings/precautions, interactions, adverse reactions, monitoring, and specific populations) using explicit label citations for each claim.